Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioma | 3 | 2023 | 3455 | 0.580 |
Why?
|
Alternative Splicing | 2 | 2012 | 1093 | 0.550 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2014 | 855 | 0.460 |
Why?
|
Histone Deacetylases | 1 | 2018 | 719 | 0.440 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 774 | 0.420 |
Why?
|
Protein Isoforms | 3 | 2014 | 1699 | 0.410 |
Why?
|
Pyrimidines | 2 | 2022 | 3027 | 0.410 |
Why?
|
RNA Polymerase II | 2 | 2014 | 539 | 0.400 |
Why?
|
NF-kappa B | 1 | 2018 | 2488 | 0.330 |
Why?
|
Glioblastoma | 4 | 2021 | 3482 | 0.320 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2022 | 350 | 0.310 |
Why?
|
DNA Damage | 1 | 2018 | 2446 | 0.300 |
Why?
|
Promoter Regions, Genetic | 4 | 2014 | 5789 | 0.300 |
Why?
|
Chromosome Mapping | 2 | 2014 | 4638 | 0.260 |
Why?
|
Brain Neoplasms | 5 | 2023 | 9031 | 0.250 |
Why?
|
Binding Sites | 1 | 2014 | 6055 | 0.240 |
Why?
|
Cerebellum | 1 | 2011 | 1500 | 0.230 |
Why?
|
Uridine | 1 | 2022 | 141 | 0.200 |
Why?
|
Gene Expression Profiling | 3 | 2014 | 9418 | 0.190 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2014 | 3639 | 0.190 |
Why?
|
Transcription, Genetic | 2 | 2011 | 7595 | 0.150 |
Why?
|
Neuroblastoma | 2 | 2022 | 1250 | 0.140 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 871 | 0.140 |
Why?
|
Genome | 3 | 2014 | 1740 | 0.130 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2021 | 3612 | 0.130 |
Why?
|
Glutamic Acid | 1 | 2021 | 1176 | 0.120 |
Why?
|
Morpholines | 1 | 2018 | 581 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1560 | 0.110 |
Why?
|
Mice, Nude | 1 | 2018 | 3614 | 0.100 |
Why?
|
Mice | 6 | 2022 | 81509 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5305 | 0.090 |
Why?
|
Computational Biology | 2 | 2014 | 3517 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2019 | 2423 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2021 | 2985 | 0.090 |
Why?
|
Drug Delivery Systems | 1 | 2021 | 2225 | 0.080 |
Why?
|
DNA Polymerase II | 1 | 2010 | 104 | 0.080 |
Why?
|
Nanoparticles | 1 | 2021 | 1955 | 0.080 |
Why?
|
Organ Specificity | 1 | 2014 | 1967 | 0.080 |
Why?
|
DNA Repair | 1 | 2018 | 2045 | 0.080 |
Why?
|
Animals | 7 | 2022 | 168441 | 0.080 |
Why?
|
Mice, Inbred Strains | 1 | 2011 | 1762 | 0.080 |
Why?
|
Neoplasms | 2 | 2019 | 22164 | 0.080 |
Why?
|
Epigenesis, Genetic | 2 | 2012 | 3798 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2019 | 3447 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4575 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3874 | 0.070 |
Why?
|
Cerebellar Neoplasms | 1 | 2011 | 586 | 0.070 |
Why?
|
Medulloblastoma | 1 | 2011 | 678 | 0.060 |
Why?
|
Viral Load | 1 | 2014 | 3330 | 0.060 |
Why?
|
Algorithms | 4 | 2015 | 14026 | 0.060 |
Why?
|
Monocytes | 1 | 2014 | 2572 | 0.060 |
Why?
|
Data Mining | 1 | 2010 | 551 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2018 | 16979 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2022 | 1405 | 0.050 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2015 | 3356 | 0.050 |
Why?
|
Proteome | 1 | 2012 | 1862 | 0.050 |
Why?
|
3-Iodobenzylguanidine | 1 | 2022 | 114 | 0.050 |
Why?
|
Neurons | 1 | 2021 | 9462 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3779 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2011 | 12796 | 0.040 |
Why?
|
Humans | 12 | 2023 | 761423 | 0.040 |
Why?
|
Antigens, CD20 | 1 | 2019 | 201 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11740 | 0.040 |
Why?
|
Apoptosis | 1 | 2014 | 9488 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 883 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2019 | 385 | 0.040 |
Why?
|
HIV-1 | 1 | 2014 | 6860 | 0.040 |
Why?
|
Child | 3 | 2023 | 80162 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8545 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2265 | 0.030 |
Why?
|
Neuroglia | 1 | 2021 | 955 | 0.030 |
Why?
|
Neurogenesis | 1 | 2021 | 862 | 0.030 |
Why?
|
Mutation | 2 | 2023 | 30045 | 0.030 |
Why?
|
Prognosis | 1 | 2014 | 29620 | 0.030 |
Why?
|
Biopsy | 1 | 2023 | 6766 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 916 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2014 | 672 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2011 | 369 | 0.020 |
Why?
|
Pyrazoles | 1 | 2019 | 2007 | 0.020 |
Why?
|
Cell Movement | 1 | 2021 | 5203 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2015 | 1027 | 0.020 |
Why?
|
HIV Infections | 1 | 2014 | 17347 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2529 | 0.020 |
Why?
|
Middle Aged | 3 | 2015 | 220826 | 0.020 |
Why?
|
Adult | 3 | 2015 | 221148 | 0.020 |
Why?
|
Exons | 1 | 2011 | 2393 | 0.020 |
Why?
|
Male | 4 | 2019 | 360736 | 0.020 |
Why?
|
Female | 4 | 2019 | 392581 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11526 | 0.010 |
Why?
|
Sequence Analysis, RNA | 1 | 2011 | 2020 | 0.010 |
Why?
|
Aged | 1 | 2014 | 169235 | 0.010 |
Why?
|
Young Adult | 2 | 2019 | 59207 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9320 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4741 | 0.010 |
Why?
|
Software | 1 | 2011 | 4434 | 0.010 |
Why?
|
Child, Preschool | 1 | 2019 | 42254 | 0.010 |
Why?
|
Brain | 1 | 2023 | 27107 | 0.010 |
Why?
|
Genomics | 1 | 2010 | 5820 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 64651 | 0.010 |
Why?
|
Cohort Studies | 1 | 2015 | 41446 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 88313 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2014 | 58956 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36423 | 0.000 |
Why?
|
Concepts
(103)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_